SLC25A24: A Calcium-Binding Mitochondrial Carrier Protein as a Potential Drug Target or Biomarker

Target Name: SLC25A24

NCBI ID: G29957

SLC25A24

SLC25A24: A Calcium-Binding Mitochondrial Carrier Protein as a Potential Drug Target or Biomarker

Abstract:
SLC25A24 is a protein that is expressed in the mitochondria and is known to play a role in the transport of calcium ions into the mitochondria. The structure and function of SLC25A24 have been studied extensively in the past, and its potential as a drug target or biomarker have been proposed. In this article, we will provide an overview of SLC25A24, its structure, function, and potential as a drug target or biomarker.

Introduction:
Mitochondria are organelles that are responsible for generating the majority of the energy for the cell in the form of ATP. They are also involved in the production of various molecules, including proteins, lipids, and derivatives. One of the proteins that is particularly well-studied in the context of mitochondria is SLC25A24.

Structure:
SLC25A24 is a member of the SLC (sodium-dependent) protein channel family 25. These channels are responsible for the transport of a variety of molecules, including ions, nutrients, and toxins into or out of the cells. SLC25A24 is characterized by a single transmembrane domain and a cytoplasmic tail. It has a calculated pI of 12.9 and a molecular weight of 37 kDa.

Function:
SLC25A24 is involved in the transport of calcium ions into the mitochondria. It is a critical protein for maintaining the proper levels of calcium ions in the mitochondria, which are essential for various cellular processes, including muscle contractions, neurotransmitter release, and signal transduction. Mutations in the SLC25A24 gene have been shown to cause a variety of cellular and mitochondrial diseases, including skeletal muscle weakness, neurodegenerative diseases, and cardiomyopathy.

Drug Target Potential:
SLC25A24 has been identified as a potential drug target due to its involvement in the transport of ions into the mitochondria. Drugs that can modulate the activity of SLC25A24, such as inhibitors of its channels or regulators of its expression, may have therapeutic benefits for a variety of diseases. For example, inhibitors of SLC25A24 have been shown to increase the amount of calcium ions in the mitochondria, which could potentially lead to muscle weakness and improve athletic performance.

Biomarker Potential:
SLC25A24 has also been identified as a potential biomarker for a variety of diseases. Its involvement in the transport of ions into the mitochondria makes it a potential indicator of muscle function and cellular energy metabolism. For example, levels of SLC25A24 have been shown to be elevated in the muscles of individuals with skeletal muscle weakness, indicating that they may have reduced muscle function. Additionally, SLC25A24 levels have been shown to be elevated in the brains of individuals with neurodegenerative diseases, suggesting that it may be involved in the progression of these conditions.

Conclusion:
SLC25A24 is a protein that is expressed in the mitochondria and is involved in the transport of calcium ions into the cells. Its structure and function have been extensively studied, and its potential as a drug target or biomarker have been proposed. Further research is needed to fully understand the role of SLC25A24 in the regulation of cellular processes and to explore its potential as a therapeutic agent.

Protein Name: Solute Carrier Family 25 Member 24

Functions: Electroneutral antiporter that mediates the transport of adenyl nucleotides through the inner mitochondrial membrane. Originally identified as an ATP-magnesium/inorganic phosphate antiporter, it also acts as a broad specificity adenyl nucleotide antiporter. By regulating the mitochondrial matrix adenyl nucleotide pool could adapt to changing cellular energetic demands and indirectly regulate adenyl nucleotide-dependent metabolic pathways (PubMed:15123600, PubMed:22015608). In vitro, a low activity is also observed with guanyl and pyrimidine nucleotides (PubMed:15123600). May play a role in protecting cells against oxidative stress-induced cell death, by buffering calcium levels in the mitochondrial matrix through the formation of calcium-phosphate precipitates (PubMed:22015608, PubMed:29100093)

The "SLC25A24 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC25A24 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets